FIELD: medicine.
SUBSTANCE: invention relates to medicine and can be used to treat soft tissue tumors whose cells express HER2 by delivering therapeutic agents to the cells of the tumor node. A method for targeted delivery of therapeutic drugs to tumor cells by intratumoral administration of a composition of hydrogel and recombinant monoclonal antibodies to HER2, in which the specified composition is administered by intratumoral injection of an implant in the form of a scaffold, which is a tube made of titanium alloy VT6, 5-10 mm long, with a wall thickness of 1±0.02 mm, with an internal diameter of 2-4 mm, with a polished outer surface and edges, having a longitudinal hole on the side of a width of 1±0.05 mm, the inner cavity of which is filled with a composition of hydrogel and recombinant monoclonal antibodies to HER2 in a 1:1 ratio.
EFFECT: invention provides minimization of mechanical traumatization of surrounding tissues during scaffold implantation, prolonged release of the immunopreparation.
1 cl, 1 ex, 1 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| TITANIUM IMPLANT WITH THE FUNCTION OF LOCAL IMMUNOTHERAPY FOR OSTEORECONSTRUCTIVE SURGERY AND PREVENTION OF LOCAL RECURRENCE OF ONCOLOGICAL DISEASE AND METHOD FOR ITS MANUFACTURE | 2021 |
|
RU2779367C1 |
| BIODEGRADABLE METAL IMPLANT FOR LOCAL IMMUNOTHERAPY OF PATIENTS WITH SOLID TUMORS | 2021 |
|
RU2780927C1 |
| BIODEGRADABLE IMPLANT FOR LOCAL IMMUNOTHERAPY OF CANCER PATIENTS | 2021 |
|
RU2780932C1 |
| RECOMBINANT TARGET TOXIN SPECIFIC TO HER2 RECEPTOR EXPRESSING CELLS | 2016 |
|
RU2627215C1 |
| SUBCUTANEOUS BIODEGRADABLE IMPLANT FOR DELAYED HEMOSTIMULATION OF CANCER PATIENTS | 2023 |
|
RU2809091C1 |
| MEANS OF IDENTIFICATION OF TUMOURS, ACQUISITIVE TO TREATMENT BY ANTIBODIES AGAINST ErbB2 | 2003 |
|
RU2338751C2 |
| RECEPTOR TARGETING CONSTRUCTS AND USES THEREOF | 2015 |
|
RU2682335C2 |
| COMBINED THERAPY FOR TREATING CANCER USING A RECOMBINANT POXVIRUS EXPRESSING A TUMOR ANTIGEN AND AN ANTAGONIST OR AGONIST OF AN IMMUNE CONTROL POINT MOLECULE | 2015 |
|
RU2724433C2 |
| COMBINATION THERAPY FOR TREATING CANCER WITH POXVIRUS EXPRESSING TUMOUR ANTIGEN AND ANTAGONIST AND/OR AGONIST OF IMMUNE CHECKPOINT INHIBITOR | 2014 |
|
RU2714142C2 |
| CONJUGATE OF LUMINESCENT SILICON DIOXIDE NANOPARTICLES WITH RECOMBINANT SINGLE-DOMAIN C7B LAMA NANO-MONOANTIBODIES, CAPABLE OF SPECIFICALLY INTERACTING WITH RECOMBINANT HER2/NEU PROTEIN - ANALOGUE OF EPIDERMAL GROWTH FACTOR NATURAL RECEPTOR EGFR/ERBB OF HUMAN CELLS | 2017 |
|
RU2679075C1 |
